StreetInsider.com News Articles

Biodesix to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 06:00:00 -0400

LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences:

Lake Street Capital Markets’ 10^th Annual Best Ideas Growth (BIG10) Conference
1x1 meetings only
Date: Thursday, September 10
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
1x1 meetings only
Date: Tuesday, September 15
Location: New York

5^th Annual Roth Healthcare Opportunities Conference
Panel and 1x1 meetings
Panel Title: The Rise of MRD Monitoring in Solid Tumors, and

Biodesix to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 06:00:00 -0400

Lake Street Capital Markets’ 10^th Annual Best Ideas Growth (BIG10) Conference
1x1 meetings only
Date: Thursday, September 10
Location: New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference
1x1 meetings only
Date: Tuesday, September 15
Location: New York

5^th Annual Roth Healthcare Opportunities Conference
Panel and 1x1 meetings
Panel Title: The Rise of MRD Monitoring in Solid Tumors, and

Form 4 BIODESIX INC For: Aug 12 Filed by: SCHULER JACK W

Thu, 13 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260813/26922818.html

Form 4 BIODESIX INC For: Aug 12 Filed by: SCHULER JACK W

Thu, 13 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260813/26922818.html

Form 4 BIODESIX INC For: Aug 10 Filed by: SCHULER JACK W

Wed, 12 Aug 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20260812/26914568.html

Form 4 BIODESIX INC For: Aug 10 Filed by: SCHULER JACK W

Wed, 12 Aug 2026 17:55:00 -0400

si-local-file:///var/storage/secattach/20260812/26914568.html

Biodesix (BDSX) PT Raised to $35 at Canaccord

Mon, 10 Aug 2026 05:48:43 -0400

Canaccord analyst Kyle Mikson raised the price target on Biodesix (NASDAQ: BDSX) to $35.00 (from $27.00) while maintaining a Buy rating.

The analyst comments "We reiterate our BUY rating on Biodesix (BDSX) shares and increase our price target to $35 from $27. Our price target increase is driven by higher revenue in 2026 and beyond in our 10-year DCF model. After the market close on Wednesday, August 5, the company reported 2Q26 results that were ahead of our estimates and FactSet consensus. Biodesix delivered another strong quarter driven by strength in Nodify test volume, improved average revenue per test and traction

Biodesix (BDSX) PT Raised to $35 at Canaccord

Mon, 10 Aug 2026 05:48:43 -0400

Canaccord analyst Kyle Mikson raised the price target on Biodesix (NASDAQ: BDSX) to $35.00 (from $27.00) while maintaining a Buy rating.

Biodesix Inc. (BDSX) Tops Q2 EPS by 19c

Wed, 05 Aug 2026 18:01:55 -0400

Biodesix Inc. (NASDAQ: BDSX) reported Q2 EPS of ($0.71), $0.19 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $26.9 million versus the consensus estimate of $25.96 million.

For earnings history and earnings-related data on Biodesix Inc. (BDSX) click here.

Form 10-Q BIODESIX INC For: Jun 30

Wed, 05 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26873996.html

Form 10-Q BIODESIX INC For: Jun 30

Wed, 05 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26873996.html

Form 8-K BIODESIX INC For: Aug 05

Wed, 05 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260805/26873668.html

Form 8-K BIODESIX INC For: Aug 05

Wed, 05 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260805/26873668.html

Biodesix Announces Second Quarter 2026 Results and Highlights

Wed, 05 Aug 2026 16:01:00 -0400

Delivered $26.9 million in revenue, representing 34% growth in Q2 2026;

Achieved 82% gross margin in Q2 2026;

Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth;

Conference Call and Webcast Today at 4:30 p.m. ET

LOUISVILLE, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2026.

“Biodesix delivered another strong quarter, highlighted by 34% revenue growth, 42% growth in

Biodesix Announces Second Quarter 2026 Results and Highlights

Wed, 05 Aug 2026 16:01:00 -0400

Delivered $26.9 million in revenue, representing 34% growth in Q2 2026;

Achieved 82% gross margin in Q2 2026;

Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth;

Conference Call and Webcast Today at 4:30 p.m. ET

“Biodesix delivered another strong quarter, highlighted by 34% revenue growth, 42% growth in

Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference

Tue, 04 Aug 2026 06:00:00 -0400

LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity’s 46^th Annual Growth Conference, which will be held from August 11-12, 2026.

Canaccord Genuity’s 46^th Annual Growth Conference
Fireside Chat Date: Wednesday, August 12, 2026
Fireside Chat Time: 3:30 PM ET
Location: InterContinental Boston, Boston, MA

The presentation will be webcast live and available for replay under “News & Events” in the Investors section

Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference

Tue, 04 Aug 2026 06:00:00 -0400

Canaccord Genuity’s 46^th Annual Growth Conference
Fireside Chat Date: Wednesday, August 12, 2026
Fireside Chat Time: 3:30 PM ET
Location: InterContinental Boston, Boston, MA

The presentation will be webcast live and available for replay under “News & Events” in the Investors section

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 06:00:00 -0400

LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2026 after the close of trading on Wednesday, August 5. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session

Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026

Wed, 22 Jul 2026 06:00:00 -0400

Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session

Form 4 BIODESIX INC For: Jun 30 Filed by: PATIENCE JOHN

Thu, 02 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260702/26728302.html

Form 4 BIODESIX INC For: Jun 30 Filed by: PATIENCE JOHN

Thu, 02 Jul 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260702/26728302.html

Roth/MKM Starts Biodesix (BDSX) at Buy

Wed, 24 Jun 2026 16:23:38 -0400

Roth/MKM analyst Max Masucci initiates coverage on Biodesix (NASDAQ: BDSX) with a Buy rating and a price target of $32.00.

For an analyst ratings summary and ratings history on Biodesix click here. For more ratings news on Biodesix click here.

Shares of Biodesix closed at $19.16 yesterday.

Form SCHEDULE 13G BIODESIX INC Filed by: Soleus Capital Master Fund, L.P.

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667085.html

Form SCHEDULE 13G BIODESIX INC Filed by: Soleus Capital Master Fund, L.P.

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667085.html

Biodesix (BDSX) PT Raised to $27 at Canaccord

Thu, 18 Jun 2026 06:57:13 -0400

(Updated - June 18, 2026 6:57 AM EDT)

Canaccord analyst Kyle Mikson raised the price target on Biodesix (NASDAQ: BDSX) to $27.00 (from $22.00) while maintaining a Buy rating.

The analyst commented: "We reiterate our BUY rating on Biodesix (BDSX) shares and raise our price target to $27 from $22. This week, we were fortunate to host investor meetings with BDSX's management team, including Scott Hutton, CEO, Robin Harper Cowie, Chief Financial Officer, and Kieran O'Kane, CCO. Investors were interested in BDSX's sales force hiring as well as increasing emphasis on PCPs. That said, management is committed to capital conservation. Moreover, investors